Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Plus Therapeutics Inc.
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
27 mars 2025 16h05 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
20 mars 2025 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
19 mars 2025 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
10 mars 2025 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
07 mars 2025 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
06 mars 2025 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with L
Plus Therapeutics Announces New Employment Inducement Grants
05 mars 2025 16h01 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Announces New Employment Inducement Grants
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
04 mars 2025 14h06 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
26 févr. 2025 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for
Patients with Leptomeningeal Metastases
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
24 févr. 2025 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary